Ichikawa, Japan

Tomo Nishimoto, Legal Representative


Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Chiba, JP (2011)
  • Ichikawa, JP (2012)

Company Filing History:


Years Active: 2011-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tomo Nishimoto: Innovator in Neurodegenerative Disease Research

Introduction

Tomo Nishimoto is a prominent legal representative and inventor based in Ichikawa, Japan. He has made significant contributions to the field of neurodegenerative disease research, holding 2 patents that focus on innovative therapeutic approaches.

Latest Patents

Nishimoto's latest patents include groundbreaking work on the Humanin receptor or humanin-like polypeptide receptor. This invention aims to identify receptors based on HN signaling pathways, revealing mechanisms that promote or suppress intracellular signal transduction for neuroprotective activity. Additionally, he has developed a method for screening HNR agonists and antagonists, which could lead to new drug treatments for neurodegenerative diseases. Another notable patent involves therapeutic agents of colivelin, which comprises a pharmaceutical composition designed to treat and prevent neurodegenerative diseases by inhibiting neuronal cell death.

Career Highlights

Throughout his career, Nishimoto has worked with various companies, including Tomohiro Chiba and Massaaki Matsuoka. His expertise in the field has allowed him to contribute to significant advancements in neurodegenerative disease therapies.

Collaborations

Nishimoto has collaborated with notable individuals such as Masaaki Matsuoka and Sadakazu Aiso, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Tomo Nishimoto's innovative work in neurodegenerative disease research exemplifies the potential of scientific advancements to improve health outcomes. His contributions through patents and collaborations continue to pave the way for future developments in this critical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…